submit to the journals

Genitourinary Cancers Journal Articles, Videos And Insights

Genitourinary Cancers: FEATURED Articles

flipper_slider

Genitourinary Cancers: Latest Articles

Genitourinary Cancers: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
Enzalutamide Treatment in Men with Nonmetastatic Prostate Cancer: Results of the PROSPER Study Katrina Mountfort
Medical Writer, Touch Medical Media, UK
Meeting Proceedings
Eisai and Merck Announce Latest Data on Lenvatinib and Pembrolizumab for Multiple Cancer Types at ASCO 2018 Katrina Mountfort
Medical Writer, Touch Medical Media, UK
Meeting Preview
EANM FOCUS 1: The First Focus Meeting of the European Association of Nuclear Medicine Katrina Mountfort, Medical Writer, Touch Medical Media, Goring-on-Thames, UK
Insight
ASCO 2017 Insight – High Dose Interleukin 2 Katrina Mountfort, Touch Medical Media, Reading, UK

Genitourinary Cancers: FEATURED VIDEOS

Editor's choice

Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for investigating radical resection of metastases followed by sorafenib in advanced renal cell carcinoma? (0:11) 2. Could you tell us a little about the RESORT study design? (1:15) 3. What were the findings of the study? (1:50) 4. Why do you think sorafenib has no effect on relapse-free survival? (3:17) 5. What will be the next steps in this clinical investigation? (4:06) Speaker disclosures: Giuseppe Procopio serves on the advisory board for Bayer, Bristol-Myers Squibb, Ipsen, Novartis and Pfizer. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Arnaud Méjean from the HEGP, Université Paris Descartes and ADHP in Paris, France, discusses the place of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma, and how this approach may change based on the results of the CARMENA trial. 1. What is the current role of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma? (0:11) 2. How did the advent of targeted therapies affect the use of cytoreductive nephrectomy? (0:32) 3. Could you tell us a little about the design of the CARMENA clinical trial? (0:58) 4. What were the findings of this study? (2:02) 5. What patients are most likely to benefit from this approach? (3:08) Speaker disclosures: Arnaud Méjean has nothing to disclose in relation to this video interview. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Genitourinary Cancers: Latest Videos

Video List based on Category on Node Page

Latest Videos

Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for...
Arnaud Méjean from the HEGP, Université Paris Descartes and ADHP in Paris, France, discusses the place of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma, and how this approach may change based on the results of the CARMENA trial. 1. What...
Editorial board member Ulka Vaishampayan from the Karmanos Cancer Center, Wayne State University, Detroit, MI, US, talks to us about the place of personalized therapy in patients with advance renal cancer and the potential role of X4P-001 in treatment paradigms in the near future. 1. What are...
Coverage of the Bayer supported satellite symposium "Radium-223 from bench to bedside and future directions for targeted alpha therapy " at TAT 2017. The video has been published on the touchONCOLOGY website with permission from Bayer.
Joe O'Sullivan discusses the role of radium-223 in the mestastatic prostate cancer treatment paradigm. Support: The filming of this video was supported by Bayer. Disclosures: Joe O'Sullivan has participated in Advisory Boards with Bayer, Sanofi and Janssen.
ESMO 2016 Immunotherapy for GU cancers: latest advances and future approaches The rapidly evolving field of immunotherapy in the treatment of genitourinary (GU) cancers was covered in a satellite symposium, sponsored by F. Hoffmann-La Roche, and held at the European Society for Medical Oncology...

LATEST TWEETS

Conference Highlights